Plain-English translation of NCT06727409 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing a medication called combined with two other medicines you may already be taking for diabetes and kidney disease. Researchers want to see if this three-medicine combination can reduce the amount of protein leaking into your urine — a sign of kidney damage — and slow down kidney disease in people with type 2 diabetes.
Many people with type 2 diabetes develop kidney disease over time, which can get worse even when taking standard medications. This trial is exploring whether adding this medication to your existing treatment plan can better protect your kidneys and prevent them from getting worse.
You likely qualify if…
You likely don't qualify if…
You would continue taking your current diabetes and kidney medications while adding the new medication () to your routine. The study involves visiting the research clinic for check-ups before starting the medication and after you've been taking it, where doctors will monitor your kidney function and protein levels through blood and urine tests. The researchers will compare your kidney health before and after starting this treatment to see if it helps protect your kidneys.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Hong Kong
Phase
Post-approval monitoring
Sponsor
Chinese University of Hong Kong
Enrollment target
~82 participants
Started
December 2024
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elaine Chow
Chinese University of Hong Kong
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.